GlaxoSmithKline's JV ViiV Healthcare says trial of injectable HIV treatment met objectives

Writer, Stock Market Wire
Thursday, August 22, 2019 - 07:41

ViiV Healthcare, a GlaxoSmithKline-Pfizer joint venture, said its injectable HIV treatment had met its primary goal in a clinical trial, reducing the number of treatments needed every year, compared to an oral treatment.

'The study met its primary endpoint, showing that the long-acting regimen of cabotegravir and rilpivirine, injected every two months, was non-inferior to cabotegravir and rilpivirine administered every month at Week 48,' the company said.

'The ATLAS-2M study results mean that people living with HIV could maintain viral suppression with six total treatments per year, instead of a daily oral treatment 365 times per year, it added.

The study was designed to demonstrate the non-inferior antiviral activity and safety of cabotegravir and rilpivirine administered every eight weeks (two months) compared to every four weeks (monthly) over a 48-week treatment period in adults living with HIV-1 infection, whose viral load was suppressed and who were not resistant to cabotegravir or rilpivirine.


Related content

Dudley helps BP overcome deadly legacy

While he will probably be disappointed with BP’s share price performance during his nine-year tenure as the oil major’s CEO, Bob Dudley will be...

Fri, 04/10/2019 - 15:15


FTSE 100 down to five female CEOs as Laury prepares to leave Kingfisher

When Kingfisher boss Véronique Laury steps down on 25 September she will become the tenth FTSE 100 CEO to do so this year, with...

Wed, 18/09/2019 - 10:43


Broker Forecast - Deutsche Bank issues a broker note on GlaxoSmithKline PLC

Deutsche Bank today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1645p (from 1620p).

Broker Forecasts data provided...

Mon, 02/09/2019 - 08:50


Temple Bar could outperform if markets turn sour

Author: 

Investors seeking a portfolio of cheap, dividend-paying stocks and selling on a 6.3% discount to net asset value (NAV) should look to Temple Bar Investment...

Thu, 29/08/2019 - 00:00


GlaxoSmithKline blood cancer treatment meets primary objective in clinical trial

GlaxoSmithKline said a clinical study of its blood cancer treatment had met its primary goal.

'The two-arm study met its primary objective and demonstrated...

Fri, 23/08/2019 - 07:16